271 related articles for article (PubMed ID: 26050659)
1. PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
Schwenzer NF; Pfannenberg AC
Semin Nucl Med; 2015 Jul; 45(4):322-31. PubMed ID: 26050659
[TBL] [Abstract][Full Text] [Related]
2. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
3. Staging and response assessment in lymphomas: the new Lugano classification.
Cheson BD
Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
[TBL] [Abstract][Full Text] [Related]
4. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
5. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
6. Minimal invasive biopsy of intraconal expansion by PET/CT/MRI image-guided navigation: a new method.
Reinbacher KE; Pau M; Wallner J; Zemann W; Klein A; Gstettner C; Aigner RM; Feichtinger M
J Craniomaxillofac Surg; 2014 Oct; 42(7):1184-9. PubMed ID: 24726395
[TBL] [Abstract][Full Text] [Related]
7. (18)F-Fluorodeoxyglucose PET/MR Imaging in Lymphoma.
Platzek I
PET Clin; 2016 Oct; 11(4):363-73. PubMed ID: 27593243
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
[TBL] [Abstract][Full Text] [Related]
9. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.
Mayerhoefer ME; Karanikas G; Kletter K; Prosch H; Kiesewetter B; Skrabs C; Porpaczy E; Weber M; Pinker-Domenig K; Berzaczy D; Hoffmann M; Sillaber C; Jaeger U; Müllauer L; Simonitsch-Klupp I; Dolak W; Gaiger A; Ubl P; Lukas J; Raderer M
Clin Cancer Res; 2014 Jun; 20(11):2984-93. PubMed ID: 24696320
[TBL] [Abstract][Full Text] [Related]
11. Impact of FDG-PET/CT in the management of lymphoma.
Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
[TBL] [Abstract][Full Text] [Related]
12. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
13. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas.
Stéphane V; Samuel B; Vincent D; Joelle G; Remy P; Francois GG; Jean-Pierre T
Eur J Radiol; 2013 Nov; 82(11):2011-7. PubMed ID: 23932096
[TBL] [Abstract][Full Text] [Related]
14. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
[TBL] [Abstract][Full Text] [Related]
15. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.
El-Galaly TC; Hutchings M
Cancer Treat Res; 2015; 165():125-46. PubMed ID: 25655608
[TBL] [Abstract][Full Text] [Related]
16. Application value of MRI combined with positron emission tomography (PET)/CT in diagnosis and preoperative staging of tongue squamous cell carcinoma.
Chen W; Zhang C; Zhang S; Liang L; Zhang B; Liu C; Zhang Z; Liang C
J Med Imaging Radiat Oncol; 2015 Apr; 59(2):170-8. PubMed ID: 25753588
[TBL] [Abstract][Full Text] [Related]
17. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
18. [The role of positron emission tomography in in lymphoma diagnosis and treatment].
Papamichael DC; Pianou NK; Chatzipavlidou V
Hell J Nucl Med; 2015; 18(2):173-9. PubMed ID: 26187221
[TBL] [Abstract][Full Text] [Related]
19. FDG PET/MR for the assessment of lymph node involvement in lymphoma: initial results and role of diffusion-weighted MR.
Platzek I; Beuthien-Baumann B; Ordemann R; Maus J; Schramm G; Kitzler HH; Laniado M; Kotzerke J; van den Hoff J
Acad Radiol; 2014 Oct; 21(10):1314-9. PubMed ID: 25086953
[TBL] [Abstract][Full Text] [Related]
20. The added value of PET/Ce-CT/DW-MRI fusion in assessment of hepatic focal lesions: PET/Ce-CT/DW-MRI fusion in hepatic focal lesion.
Salem S; Houseni M; Zidan L; Kandil A
Nucl Med Biol; 2015 Jul; 42(7):637-42. PubMed ID: 25907467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
